1-(4-benzylphenyl)piperazine | 345218-88-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-benzylphenyl)piperazine
• CAS: 345218-88-4
• 化学式: C₁₇H₂₀N₂
• 分子量: 252.359
• InChiKey: CRVRGEZHMOCDHL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-benzylphenyl)piperazine 、 N-(2,6-Dichloro-phenyl)-4-methyl-N-oxiranylmethyl-benzenesulfonamide 生成 N-[3-[4-(4-benzylphenyl)piperazin-1-yl]-2-hydroxypropyl]-N-(2,6-dichlorophenyl)-4-methylbenzenesulfonamide;dihydrochloride
  参考文献：
  名称：

  DESCAMPS, M.;GOLDENBERG, C.

  摘要：

  DOI：

文献信息

• Synthesis and Anticonvulsant Activity of New N-Mannich Bases Derived from 5-Cyclopropyl-5-phenyl-hydantoins
  作者：Hanna Byrtus、Jolanta Obniska、Anna Czopek、Krzysztof Kamiński

  DOI：10.1002/ardp.201000241

  日期：2011.4

  Synthesis, physicochemical and anticonvulsant properties of new N‐Mannich bases 3–24 derived from 5‐cyclopropyl‐5‐phenyl‐ and 5‐cyclopropyl‐5‐(4‐chlorophenyl)‐hydantoins were described here. Initial anticonvulsant screening was performed using intraperitoneal (i.p.) maximal electroshock (MES) and subcutaneous pentylenetetrazole (scPTZ) seizures tests. Selected derivatives were also screened in the

  本文描述了衍生自 5-环丙基-5-苯基-和 5-环丙基-5-（4-氯苯基）-乙内酰脲的新型 N-曼尼希碱 3-24 的合成、理化和抗惊厥特性。使用腹膜内 (ip) 最大电击 (MES) 和皮下戊四唑 (scPTZ) 癫痫试验进行初始抗惊厥筛查。在 6 Hz 测试中也筛选了选定的衍生物。应用旋转棒试验确定神经毒性。药理结果表明，大多数化合物在 MES 和/或 scPTZ 测试中有效。大鼠口服给药后的定量研究表明，几种分子比用作参考抗癫痫药物的苯妥英和乙琥胺更有效。
• [EN] PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE<br/>[FR] MODULATEURS PHÉNYLPIPÉRAZINE PROPROTÉINE CONVERTASE SUBTILISINE/KEXINE DE TYPE 9 (PCSK9) ET LEUR UTILISATION
  申请人：PORTOLA PHARM INC

  公开号：WO2017034997A1

  公开（公告）日：2017-03-02

  This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.

  这项发明涉及PCSK9生物学领域，以及小有机化合物作为调节PCSK9生物活性的配方和使用方法。具体而言，该发明提供了调节低密度脂蛋白循环水平的小有机化合物组合物，通过改变蛋白质PCSK9的构象来实现。将这些小有机化合物配体结合到PCSK9上会改变蛋白质的构象，修改PCSK9与内源性低密度脂蛋白受体之间的相互作用，从而导致循环LDL胆固醇水平降低或增加。高LDL胆固醇水平与心脏疾病风险增加相关。低LDL胆固醇水平可能在其他疾病情况下有问题，比如肝功能障碍；因此，开发能够提高LDL水平的小有机化合物配体也具有实用性。
• BIARYL NITROGEN-HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION
  申请人：SANDANAYAKA Vincent

  公开号：US20070149544A1

  公开（公告）日：2007-06-28

  The present invention relates to a chemical genus of biaryl nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.

  本发明涉及一种化学类别的双芳基氮连接杂环的化合物，它们是LTA4H（白三烯A4水解酶）的抑制剂。这些化合物具有下列的一般式：它们可用于治疗、预防和预防炎症性疾病和疾患。
• Process for making N-((4-phenyl) methylphenyl) piperazines
  申请人：SUNTORY LIMITED

  公开号：EP1138678A2

  公开（公告）日：2001-10-04

  1. A process for producing a compound having the formula (XII'): wherein Q' represents an optionally substituted phenyl group and X represents a hydrogen atom, a halogen atom, an alkoxy group, or an optionally substituted alkyl group, that process comprises reacting a benzophenon derivative having the formula (XIII): wherein Q' and X are the same as defined above, and L represents a group which can be easily exchanged with an amino group, with a piperazine derivative having the formula (XIV): wherein W represents a hydrogen atom, a benzyl group, a p-methoxybenzyl group, a benzyloxycarbonyl group, a p-methoxybenzyloxycarbonyl group, a p-nitrobenzyloxycarbonyl group, a tert-butoxycarbonyl group, an ethoxycarbonyl group or an acetyl group to give a compound having the formula (XV): wherein Q', W and X are the same as defined above, and the subsequent reduction and deprotection of the compound having the formula (XV).

  1.一种生产具有式 (XII') 的化合物的工艺： 其中 Q'代表任选取代的苯基，X 代表氢原子、卤素原子、烷氧基或任选取代的烷基，该工艺包括使具有式 (XIII)： 其中 Q' 和 X 与上式定义相同，L 代表易于与氨基交换的基团，该工艺包括将具有式（XIV）的哌嗪衍生物与具有式（XIII）的苯甲酮衍生物反应： 其中 W 代表氢原子、苄基、对甲氧基苄基、苄氧羰基、对甲氧基苄氧羰基、对硝基苄氧羰基、叔丁氧羰基、乙氧羰基或乙酰基，得到式（XV）的化合物： 其中 Q'、W 和 X 与上文所定义的相同，随后对具有式（XV）的化合物进行还原和脱保护。
• Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use
  申请人：SRX Cardio, LLC

  公开号：US10568882B2

  公开（公告）日：2020-02-25

  This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.

  本发明涉及 PCSK9 生物学领域以及小分子有机化合物作为配体用于调节 PCSK9 生物活性的组合物和使用方法。特别是，本发明提供了通过改变蛋白质 PCSK9 的构象来调节低密度脂蛋白循环水平的小分子有机化合物组合物。将这些小分子有机化合物配体与 PCSK9 结合可改变该蛋白的构象，改变 PCSK9 与内源性低密度脂蛋白受体之间的相互作用，并可导致循环中低密度脂蛋白胆固醇水平的降低或升高。低密度脂蛋白胆固醇水平高与心脏病风险增加有关。低密度脂蛋白胆固醇水平低可能会对肝功能障碍等其他疾病造成困扰；因此，能提高低密度脂蛋白水平的小分子有机化合物配体也很有用。